Approximately half of children with neuroblastoma—a childhood cancer that develops from immature nerve cells—have a form that indicates a high likelihood of recurrence. New findings published by Wiley online in Cancer show that a “bridge therapy” between induction and consolidation treatments may benefit patients with this high-risk neuroblastoma.